Popular Hemp

Press Release: Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries

DENVER–(BUSINESS WIRE)–Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (“Mydecine” or the “Company”) is pleased to announce the previously announced spin-out transaction, to be implemented through a statutory plan of arrangement (the “Arrangement”) between Mydecine and ALT House Cannabis Inc. (“Spinco”) has received the requisite shareholder approval at Mydecine’s annual general and special meeting of shareholders held September 20, 2021 (the “Meeting”). Mydecine shareholders have voted 99.939% in favour of approving the Arrangement at the Meeting, and the Company received final approval of the Supreme Court of British Columbia on September 24, 2021.

Completion of the Arrangement and the spin-out transaction remains subject to certain conditions, including final acceptance by the Aequitas Neo Exchange. If the approval of the Aequitas Neo Exchange is received and all other conditions precedent to the Arrangement are satisfied or waived, Mydecine expects to complete the Arrangement on or about October 1, 2021.

At the Meeting, six of the seven director nominees listed in Mydecine’s management information circular dated August 23, 2021 (the “Circular”, available on the Company’s website at https://www.mydecine.com/ and on SEDAR at www.sedar.com) were elected as directors, with Andre Peschong no longer acting as a director of the Company. Directors have been elected to serve until the close of the next annual meeting of shareholders. The detailed results of the vote are set out below.

Nominee:

Votes For:

% Votes For

Votes Withheld

%Votes Withheld

David Joshua Bartch

42,323,083

90.245%

4,575,099

9.755%

Damon Michaels

44,569,486

95.035%

2,328,696

4.965%

Gordon Neal

45,442,567

96.896%

1,455,615

3.104%

Josephine Wu

45,432,115

96.874%

1,466,067

3.126%

Robert Roscow

45,435,948

96.882%

1,462,234

3.118%

Dr. Saeid Babaei

42,875,838

91.423%

4,022,344

8.577%

In addition, at the Meeting, Mydecine shareholders approved the appointment of MNP LLP as the auditor of Mydecine for the ensuing year, the adoption of the New Mydecine Equity Incentive Plan, and the adoption of the Spinco Stock Option Plan, all as defined and described in the Circular.

On behalf of the Board of Directors:
David Joshua Bartch
David Joshua Bartch, Chief Executive Officer

0 thoughts on “Press Release: Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries”

Write a Reply or Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.